Patent DE1006117B successfully refreshed from Google Patents.
US5597578A
Expired / Lapsed
US
⏱️ 0.0 years remaining
TGF-β protein compositions for inhibition of cell proliferation
Assignee: Oncogen LP
•
Filing: 1994-04-28
•
Granted: 1997-01-28
•
Expires: 2014-04-28
Abstract
Abstract Antiproliferative compositions are provided which are capable of sustained release of an antiproliferative agent, particularly a TGF- beta , at a site proximal to a target cell. The compositions are effective in inhibiting proliferation of the target cell, particularly when used in combination with a vasoconstrictive agent.
Inventors
- 👤 Dennis M. Brown
- 👤 Edward Luck
- 👤 Daniel R. Twardzik
- 👤 Anthony F. Purchio
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 16:40
CPC Classifications
C; C07; C07K; C07K14/00; A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K38/00; A61K38/16; A61K38/17; A61K38/18; A61K38/1841; A61K47/00; A61K47/30; A61K47/42; A61K47/50; A61K47/51; A61K47/62; A61K47/64; A61K47/642; A61P; A61P35/00
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
69 words
In a method for inhibiting proliferation of cells sensitive to TGF-β1 by contacting said cells with an antiproliferative composition, the improvement which comprises: an antiproliferative composition consisting essentially of an amorphous, viscous, injectable proteinaceous matrix comprising a uniform dispersion of collagen fibrils in a physiologically acceptable aqueous medium and wherein said matrix contains TGF-β1 in an amount sufficient, when released from said matrix, to inhibit proliferation of said cells.
Claim 2
Dependent Claim
69 words
In a method for inhibiting proliferation of cells sensitive to TGF-β1 by contacting said cells with an antiproliferative composition, the improvement which comprises: an antiproliferative composition consisting essentially of an amorphous, viscous, injectable proteinaceous matrix comprising a uniform dispersion of collagen fibrils in a physiologically acceptable aqueous medium and wherein said matrix contains TGF-β1 in an amount sufficient, when released from said matrix, to inhibit proliferation of said cells.
Claim 3
Dependent Claim
12 words
The method according to claim 1, wherein said TGF-β1 is simian TGF-β1.
Claim 4
Dependent Claim
34 words
The method according to claim 1, wherein said TGF-β1 is at a concentration of from about 1 ng/ml to about 10 mg/ml, and the concentration of said collagen is about 10 to 40 mg/ml.
Claim 5
Dependent Claim
29 words
The method according to claim 1, wherein said matrix further contains a vasoconstrictive agent in an amount sufficient to retard diffusion of said TGF-β1 away from said collagen matrix.
Claim 6
Dependent Claim
12 words
The method according to claim 4, wherein said vasoconstrictive agent is epinephrine.
Claim 7
Dependent Claim
12 words
The method of claim 1 wherein the collagen is bovine skin collagen.
Claim 8
Dependent Claim
14 words
The method of claim 1 wherein the TGF-β1 is uniformly dispersed in said matrix.
Claim 9
Dependent Claim
50 words
A pharmaceutical composition for inhibiting cell proliferation consisting essentially of an amorphous, viscous, injectable proteinaceous matrix comprising a uniform dispersion of collagen fibrils in a physiologically acceptable aqueous medium and wherein said matrix contains TGF-β1 in an amount sufficient, when released from said matrix, to inhibit proliferation of said cells.
Claim 10
Dependent Claim
50 words
A pharmaceutical composition for inhibiting cell proliferation consisting essentially of an amorphous, viscous, injectable proteinaceous matrix comprising a uniform dispersion of collagen fibrils in a physiologically acceptable aqueous medium and wherein said matrix contains TGF-β1 in an amount sufficient, when released from said matrix, to inhibit proliferation of said cells.
Claim 11
Dependent Claim
36 words
The composition of claim 8, wherein the collagen is at a concentration of from about 10 mg/ml to about 40 mg/ml and the TFG-β1 is at a concentration of from about 1 ng/ml to 10 mg/ml.
Claim 12
Dependent Claim
11 words
The composition of claim 9, wherein the TGF-β1 is simian TGF-β1.
Claim 13
Dependent Claim
28 words
The composition of claim 8 wherein said matrix further contains a vasoconstrictive agent in an amount sufficient to retard diffusion of said TGF-β1 away from said collagen matrix.
Claim 14
Dependent Claim
11 words
The composition of claim 11, wherein said vasoconstrictive agent is epinephrine.
Claim 15
Dependent Claim
12 words
The composition of claim 8 wherein the collagen is bovine skin collagen.
Claim 16
Dependent Claim
14 words
The composition of claim 8 wherein the TGF-β1 is uniformly dispersed in said matrix.
References Cited (Backward Citations)
US4837285A
Cited
USRE33375E
Cited
US4774228A
Cited
US4760131A
Cited
US4978332A
Cited
US4950483A
Cited
US5024841A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-01-28 | 2000-07-29 | 2001-01-28 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-01-28 | 2004-07-29 | 2005-01-28 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-01-28 | 2008-07-29 | 2009-01-28 | $7700.00 | Window Closed / Lapsed |